t******r
发帖数: 8600 | 1 这位ID疼失亲人的心情我理解，由此而来的偏执和对他人言辞的故意歪曲和过度攻击也
可以理解。相信不是恶意。
下面是Merck药厂最新免疫治疗药物的最新临床试验数据：药物将病人的寿命从对照组
的十一个月延长到十三、四个月。另外一家药厂BMY（施贵宝）同类药物的疗效类似，
最近在治疗另外一类肿瘤的临床实验中还缩短了病人的寿命。这些资料都是公开的，任
何人都可以上网查查。你说的基因配型我理解为检测PD-1的表达水平。你亲人通过了表
明他/她本身的免疫功能比其他病人强。可以说很幸运。
圣诞快乐!
October 08, 2016 08:45 AM Eastern Daylight Time
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside
the United States and Canada, toMerck Announces Longer-Term Follow-Up of
Overall Survival Data for KEYTRUDA® (pembrolizumab) in... 阅读全帖 |
|
y*****l
发帖数: 5997 | 2 T-DM1 Significantly Improved Progression-Free Survival in Randomized Phase
II Trial
3 hours 20 minutes ago - BIZ via Comtex
BusinessWireImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today announced that
Roche has disclosed positive top-line results from the first randomized
trial assessing trastuzumab emtansine (T-DM1, previously known as
trastuzumab-DM1) in HER2-positive metastatic breast cancer (MBC). T-DM1
consists of Immuno... 阅读全帖 |
|
N*******g
发帖数: 370 | 3 ·方舟子·
武汉协和医院多名妇产科医生被查出患有甲状腺癌一事引起了舆论很大的关
注。即使普通人也不难理解，多名同一科室的医生集中爆发一种并不常见的非传
染性疾病，只能说明其工作环境有问题。但有的专业人士却不这么认为。除了院
方简单地发表了一个声明声称工作环境检测结果正常外，更有人试图从理论上证
明甲状腺癌高发与电离辐射无关。
武汉协和医院乳腺甲状腺外科黄韬教授认为，射线不是甲状腺癌发病主因，
更不是唯一原因。医学上所说的由射线引发甲状腺癌，特指广岛长崎核爆和切尔
诺贝利核泄漏以后，幸存者中的癌症发病人群。
（http://news.ifeng.com/mainland/detail_2013_02/23/22403505_0.shtml ）
我手头有美国斯坦福大学医学院教授I. Ross McDougall写的《临床甲状腺
癌》（Thyroid Cancer in Clinical Practice，2007年版）一书，该书指出：
“辐射和遗传是（引发甲状腺癌的）两个重要因素。辐射引起能致癌的突变。……
不同剂量的辐射对甲状腺有不同的效果，组织接受中间剂量（0.1~... 阅读全帖 |
|
|
|
j******9
发帖数: 3 | 6 A strong data is about to be released at ESMO on 9/29 |
|
|
|
|
D******9
发帖数: 2665 | 10 Exelixis, Inc. (EXEL) today announced that its lead compound, cabozantinib,
will be the subject of three clinical data presentations at the European
Society for Medical Oncology (ESMO) 2012 Congress. During the meeting, which
will be held from September 28 to October 2, 2012, in Vienna, Austria,
investigators will present data from ongoing trials of cabozantinib in
medullary thyroid cancer, castration-resistant prostate cancer, and non-
small cell lung cancer. |
|
y*****l
发帖数: 5997 | 11 报导日期：2012/10/01 12:04
美股周一盘中上涨
美股周一盘中上涨。美国制造业活动回升优於预期，带动美股强劲上扬，道琼早盘涨逾
1%。
道琼工业指数盘中上涨144.49点，来到13581.62点，涨幅1.08%。那斯达克指数上涨13.
14点，来到3129.36点，涨幅0.42%。标准普尔500指数上涨11.57点，来到1452.22点，
涨幅0.80%。
美国商务部周一公布，8月份营建支出下滑0.6%，不如分析师原先预估的成长0.5%。
美国供给管理学会周一公布，9月份制造业数升至51.5点，由前一个月的49.6萎缩恢复
为成长，亦为5月以来最高。
Gordmans Stores (GMAN) 公司将第三季(10月为止)每股盈余目标从0.24-0.26美元调降
至0.18-0.20美元，市场预期0.26美元；营收目标从1.45-1.47亿调降至1.42-1.44亿美
元，市场预期1.4647亿美元，同店销售预期下跌2.1%。公司预估也将第四季每股盈余目
标从0.62-0.65调降至0.58-0.61美元，市场预期0.64美元；营收目标从2.17-2.19亿调
... 阅读全帖 |
|
E****e
发帖数: 315 | 12 from SeekingAlpha
The recent news announcing Genentech’s (DNA) receipt of a “Refuse to File
(RTF)” letter from the FDA for the accelerated approval of the Biologic
License Application (BLA) for trastuzumab-DM1 (T-DM1) has caused a sell-off
in Immunogen, the owner of the technology and partner on the drug with Roche
. According to the FDA letter, the refusal to give the early approval was
because “the trials had not yet exhausted all available drugs approved for
metastatic breast cancer, regardle... 阅读全帖 |
|
E****e
发帖数: 315 | 13 from SeekingAlpha
The recent news announcing Genentech’s (DNA) receipt of a “Refuse to File
(RTF)” letter from the FDA for the accelerated approval of the Biologic
License Application (BLA) for trastuzumab-DM1 (T-DM1) has caused a sell-off
in Immunogen, the owner of the technology and partner on the drug with Roche
. According to the FDA letter, the refusal to give the early approval was
because “the trials had not yet exhausted all available drugs approved for
metastatic breast cancer, regardle... 阅读全帖 |
|
